Clinical trials: Major Depressive Episode
Depression
Measuring Response to Depression Treatment
The primary goal of this study is to compare a new symptoms rating questionnaire, called the Vancouver Semi-Structured Interview for Depression (V-SID), to the traditionally used questionnaires.
- Trial name
- NCT00924183
- Testing
- Treatment-as-usual
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc.
Major Depressive Episode Associated With Bipolar II Disorder
To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.
This is a randomized, double-blind, placebo-controlled pilot study aiming to evaluate the effects of NMRA-335140 on symptoms of major depression in adults with Bipolar (BP) II disorder.
- Trial name
- NCT06429722
- Testing
- NMRA-335140 80 mg
- Where
- 21 sites in United States
- Volunteers
- 18 people
- Sponsor
- Neumora Therapeutics, Inc.
Major Depression, Bipolar Disorder
Longitudinal Study of People Presenting for First Treatment of a Mood Disorder
The goal of this project is to study the course and outcome of illness in individuals who present with a first episode of depression or mania, or who have a recurrent disorder but have never received treatment.
- Trial name
- NCT01529905
- Where
- Canada
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- McMaster University
Depressive Episode, Depression
Sleep Signal Analysis for Current Major Depressive Episode (SAMDE)
The objective of this study is to collect data to finalize the development of MEB-001 software as a medical device. The data collected in this study will be used to develop MEB-001 machine learning algorithms by training the…
- Conditions
- Depressive Episode, Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- SAMDE (NCT05708222)
- Testing
- MEB-001
- Where
- 13 sites in United States
- Volunteers
- 715 people
- Sponsor
- Medibio Limited
Major Depressive Disorder, Severe Depressive Episode Without Psychotic Symptoms
The Friendship Bench Plus Trial
The goal of this randomised controlled trial is to enhance the Friendship Bench intervention with antidepressants in adults with moderate to severe depression. The main questions it aims to answer are: 1.
- Trial name
- NCT06384209
- Testing
- Fluoxetine, Sertraline Pill, Friendship Bench Intervention- Problem Solving Therapy
- Where
- Zimbabwe
- Volunteers
- 296 people
- Sponsor
- University of Bern
Depressive Episode, Major Depressive Disorder
Pre-mapping Networks for Brain Stimulation 2
The investigators compare the primary and secondary outcome measures using accelerated intermittent theta burst stimulation (aiTBS, 20 sessions active and 20 sessions sham in a counterbalanced crossover design) to treat…
- Trial name
- PreNeSt2 (NCT05260086)
- Testing
- Neuronavigated aiTBS
- Where
- Germany
- Volunteers
- 92 people
- Sponsor
- University Medical Center Goettingen
Bipolar II Disorder, Most Recent Episode Major Depressive
The Role of iTBS in Bipolar II Depression
There is a paucity of evidence-supported treatment choices for bipolar II depression (BD-II depression), hindered by multiple comorbidity and manic switch. In addition, a slower response also burdens the patients.
- Trial name
- NCT04998097
- Testing
- repetitive transcranial magnetic stimulation (rTMS)
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Major Depressive Episode
Pain Perception in Suicidal Behavior Vulnerability
In France, almost 1 death on 50 is a suicide. The suicide occurs in unbearable psychic pain where mental trouble has a major influence. It is classified as preventable mortality.
- Trial name
- DOCS (NCT02915679)
- Testing
- Blood sample for genetic purpose, psychiatric assessment and pain investigation
- Where
- France
- Volunteers
- 167 people
- Sponsor
- University Hospital, Montpellier
Major Depressive Episode, Inflammatory Bowel Diseases
Microglial Activation in Inflammatory Bowel Disease
The purpose of this study is to monitor microglial activation in participants with inflammatory bowel disease (IBD) and investigate the relationship that exists between these patients and their risk of acquiring major depressive…
- Trial name
- NCT03487926
- Testing
- [18F]FEPPA
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Episode (MDE), Major Depressive Disorder (MDD)
LHC-CIDI-5 in Hong Kong
The World Health Organization Composite International Diagnostic Interview-5th (CIDI-5) is a standardized diagnostic tool used to assess the prevalence of mental and substance use disorders over varying time frames (30 days, 12…
- Conditions
- Major Depressive Episode (MDE), Major Depressive Disorder (MDD), Persistent Depressive Disorder (PDD), Suicidal Ideation
- Trial name
- NCT06804525
- Testing
- CIDI-5, LHC-CIDI-5
- Where
- Hong Kong
- Volunteers
- 2,500 people
- Sponsor
- The University of Hong Kong
Schizophrenia, Schizoaffective Disorder
Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH)
Major depressive episodes (MDEs) occur frequently during the course of psychotic disorders, and several antidepressive agents have been successfully applied.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Delusional Disorder
- Trial name
- AGOPSYCH (NCT01822418)
- Testing
- agomelatine
- Where
- Germany
- Volunteers
- 27 people
- Sponsor
- Central Institute of Mental Health, Mannheim
Depression, Depressive Disorders
A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjunctive Therapy in Subjects With Psychotic Major Depression (28130)(P05845)
The primary purpose of this study is to determine whether subjects with psychotic major depression benefit from adjunctive treatment with Org 34517.
- Conditions
- Depression, Depressive Disorders, Psychotic Disorders
- Trial name
- Hermes (NCT00212797)
- Testing
- Org 34517
- Volunteers
- 273 people
- Sponsor
- Merck Sharp & Dohme LLC
Major Depressive Disorder, Major Depressive Episode
Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN)
Predictive factors and biomarkers of response to antidepressants in major depressive disorder are scarce. Beta-arrestins are proteins which inhibit G Protein Coupled Receptors and desensitize serotonergic and dopaminergic…
- Trial name
- DEPARRESTCLIN (NCT02051413)
- Testing
- Venlafaxine extended release
- Where
- France
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Major Depressive Episode
Comparing Uni- and Bi-lateral TBS in Major Depression
Repetitive transcranial magnetic stimulation (rTMS) is a Health Canada approved treatment for major depression. Theta burst stimulation (TBS) is a very promising new treatment for major depression that allows a 15-fold reduction…
- Trial name
- NCT04142996
- Testing
- Theta burst stimulation
- Where
- Canada
- Volunteers
- 256 people
- Sponsor
- The Royal Ottawa Mental Health Centre
Major Depressive Disorder, Hepatitis C, Chronic
Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients
The purpose of this study is to determine whether the use of an antidepressant (escitalopram) can prevent depressive episodes that appear during the treatment with peg-interferon and ribavirin in patients with chronic hepatitis C.
- Trial name
- NCT00166296
- Testing
- Escitalopram
- Where
- 15 sites in Spain
- Volunteers
- 133 people
- Sponsor
- Germans Trias i Pujol Hospital
Major Depressive Episode, Borderline Personality Disorder
Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics
This neuroimaging study is a clinical trial investigating the effectiveness of intermittent theta-burst transcranial magnetic stimulation (iTBS-TMS) to the inferior parietal lobule (IPL) in reducing suicide risk in patients with…
- Conditions
- Major Depressive Episode, Borderline Personality Disorder, Suicide
- Trial name
- NCT04130958
- Testing
- Intermittent Theta Burst Transcranial Magnetic Stimulation (Active)
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Massachusetts General Hospital
Bipolar Depression
Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes
The purpose of this study was to evaluate the efficacy, safety, and pharmacokinetics of switching FK949E (sustained-release quetiapine) 50-mg and 150-mg tablets to the other tablet at the equivalent total daily dose in bipolar…
- Trial name
- NCT02362412
- Testing
- FK949E
- Where
- 7 sites in Japan
- Volunteers
- 22 people
- Sponsor
- Astellas Pharma Inc
Depressive Disorder, Suicidal Ideas
Evaluation of the Efficacy and Safety of Subcutaneous Ketamine in the Treatment of Depressive Episode With Suicidal Ideation and/or Behavior in Adolescents
Evaluate the efficacy and safety of subcutaneous ketamine added to usual treatment in the management of depressive episodes with suicidal ideation or behavior in adolescent patients, compared to usual treatment added to placebo…
- Trial name
- NCT06957704
- Testing
- ketamine, Midazolam
- Volunteers
- 60 people
- Sponsor
- Federal University of São Paulo
Major Depressive Episode
A Study Comparing Oral Ketamine With Oral Midazolam for the Treatment of Major Depressive Episodes
Patients with depression are acutely distressed, often suicidal, and unable to meet the demands of everyday life. If proven effective in a rigorously conducted multicenter randomized controlled trial (RCT), oral ketamine would…
- Trial name
- KOMET (NCT07839338)
- Testing
- Oral ketamine, Oral midazolam
- Where
- 5 sites in India
- Volunteers
- 220 people
- Sponsor
- Jawaharlal Institute of Postgraduate Medical Education & Research
Relapse Rate of a Major Depressive Episode, Safety of Olanzapine in Subjects With Major Depression
Optimal Duration of Olanzapine Add-on Therapy in Major Depression
Evaluation of olanzapine versus placebo in the continuation therapy of subjects with major depression who had a response with additional olanzapine to an antidepressant.
- Trial name
- OLA-D (NCT00568672)
- Testing
- Olanzapine
- Where
- Germany
- Sponsor
- Charite University, Berlin, Germany